Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-168 monotherapy or with toripalimab in advanced solid tumours
NCT06868199Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of LM-168 in solid tumor (advanced stage), sponsored by LaNova Medicines. Started May 2025; status: recruiting.
02
Drugs
LM-168
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06868199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868199.